Semaglutide

Background

Semaglutide is a long‑acting glucagon‑like peptide‑1 receptor agonist (GLP‑1 RA) developed by Novo Nordisk for once‑weekly treatment of type 2 diabetes mellitus (T2D) and, subsequently, chronic weight management and obesity.[11][9] It is marketed as Ozempic (subcutaneous for T2D and cardiovascular risk reduction), Rybelsus (oral for T2D), and Wegovy (subcutaneous for chronic weight management).[11][2] Semaglutide is a modified analog of human GLP‑1 (7–37) with 94% sequence homology, engineered to enhance resistance to dipeptidyl peptidase‑4 (DPP‑4) degradation and to prolong systemic exposure via albumin binding, enabling once‑weekly dosing.[11][9]

Discovery of semaglutide followed earlier work on liraglutide, another acylated GLP‑1 analog, and built on a strategy of fatty‑acid acylation to increase half‑life while retaining GLP‑1 receptor activity.[11][4][9] Medicinal chemistry optimization identified a C18 fatty diacid attached via a spacer to Lys26 and an amino acid substitution at position 8 (Aib8) to confer DPP‑4 resistance and strong reversible albumin binding.[9][11] Subcutaneous semaglutide was first approved by the US Food and Drug Administration (FDA) in 2017 for T2D, followed by oral semaglutide in 2019, and a higher‑dose subcutaneous formulation in 2021 for chronic weight management.[2][11]

Mechanism of action

Semaglutide is a selective GLP‑1 receptor (GLP‑1R) agonist that mimics endogenous incretin GLP‑1.[11][4] GLP‑1R is expressed in pancreatic islets, gastrointestinal tract, heart, kidney, and multiple brain regions involved in appetite and energy balance.[4][13]

At the pancreatic level, semaglutide:

• Enhances glucose‑dependent insulin secretion from β‑cells.[11]
• Suppresses glucagon secretion from α‑cells when plasma glucose is elevated, reducing hepatic glucose production.[11]
• May support β‑cell function and survival in preclinical models.[4]

In the gastrointestinal tract and peripheral tissues, semaglutide:

• Slows gastric emptying, contributing to reduced postprandial glucose excursions, particularly early in treatment.[11]
• Modestly reduces body weight through effects on appetite and energy intake rather than energy expenditure.[11][13]

In the central nervous system, semaglutide exerts anorectic effects via GLP‑1Rs in hypothalamic and brainstem nuclei that regulate food intake.[13] In rodent models, subcutaneous semaglutide accessed circumventricular regions and reduced food intake, altered food preference, and produced sustained weight loss without reducing energy expenditure, consistent with a primary effect on appetite and hedonic feeding.[13]

Semaglutide also exerts cardiometabolic effects, including modest reductions in systolic blood pressure, improvements in lipid parameters, and reductions in inflammatory markers, which may contribute to observed cardiovascular (CV) benefit in outcome trials.[11][4]

Evidence summary

Glycemic control and T2D management

The SUSTAIN program (subcutaneous semaglutide) comprises multiple phase 3 randomized controlled trials (RCTs) in T2D.[11]

• SUSTAIN 1: 30‑week, placebo‑controlled RCT in 388 patients with T2D inadequately controlled with diet/exercise; once‑weekly semaglutide 0.5 or 1.0 mg achieved HbA1c reductions up to ~1.5–1.6% and weight loss of 3.5–4.3 kg versus placebo.[11]
• SUSTAIN 2–5, 7: Active‑comparator trials vs sitagliptin, exenatide ER, insulin glargine, and others generally showed greater HbA1c reduction (~1.1–1.8%) and greater weight loss (up to ~6–7 kg) with semaglutide 0.5–1.0 mg once weekly.[11]

The PIONEER program evaluated oral semaglutide in T2D.[2][11]

• In multiple phase 3 RCTs (e.g., PIONEER 1–10), oral semaglutide at doses up to 14 mg once daily produced HbA1c reductions of ~1.0–1.5% and weight loss of ~2–5 kg, often superior to placebo, sitagliptin, and in some trials empagliflozin, with safety broadly consistent with injectable GLP‑1 RAs.[2][11]

Cardiovascular outcomes

• SUSTAIN‑6: A CV outcome trial in 3,297 patients with T2D and high CV risk randomized to semaglutide 0.5 or 1.0 mg weekly vs placebo on standard of care for a median of 2.1 years.[11] Semaglutide significantly reduced the composite major adverse cardiovascular events (MACE: CV death, nonfatal myocardial infarction, or nonfatal stroke) by 26% versus placebo (hazard ratio ~0.74), establishing CV safety and suggesting benefit.[11]

• Subsequent analyses and meta‑analyses have supported a consistent MACE risk reduction across GLP‑1 RAs, with semaglutide among agents showing significant CV benefit in high‑risk T2D populations.[11]

Obesity and chronic weight management

The STEP program evaluated higher‑dose semaglutide (2.4 mg once weekly) for chronic weight management in people with obesity or overweight.

• STEP 1: Double‑blind RCT in 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidities) without diabetes; semaglutide 2.4 mg weekly plus lifestyle intervention produced mean body‑weight reduction of ~14.9% vs 2.4% with placebo at 68 weeks.[15][14]
• STEP 2–4 and others: Demonstrated substantial weight loss (~9–17% depending on population and comparator), improvements in glycemic control in those with T2D, and favorable effects on cardiometabolic risk factors.[14][15]

A 2024–2025 review describes semaglutide as providing among the largest weight reductions reported with pharmacotherapy for obesity and notes sustained benefit over at least 2 years in extension studies, although data beyond this duration remain limited.[14][15]

Liver and metabolic‑associated fatty liver disease (MAFLD)

A single‑centre longitudinal study in 75 patients with T2D and MAFLD treated with semaglutide (0.25 mg/week titrated to 0.5 mg/week for 12 weeks) reported significant improvements in HbA1c, BMI, insulin resistance (HOMA‑IR), liver stiffness, liver enzymes, and inflammatory markers, accompanied by proteomic and metabolomic changes consistent with improved hepatic metabolism.[6] This supports a potential role in MAFLD, although larger controlled trials are needed.[6]

Preclinical mechanistic work

In rodent studies, semaglutide consistently reduced body weight, food intake, and adiposity, and improved glucose tolerance, with effects mediated via central GLP‑1R‑expressing neural circuits.[13] Acute and chronic dosing studies have shown modulation of hypothalamic appetite‑regulating neurons and changes in reward‑related feeding behavior.[13]

Clinical and research uses

Approved clinical indications

Based on FDA and EMA decisions and pivotal clinical programs:[11][2][14]

• Type 2 diabetes mellitus

  • Subcutaneous semaglutide (Ozempic) is approved as an adjunct to diet and exercise to improve glycemic control in adults with T2D.
  • Oral semaglutide (Rybelsus) is approved with the same core indication in adults with T2D.

• Cardiovascular risk reduction in T2D

  • Subcutaneous semaglutide is approved to reduce the risk of major CV events in adults with T2D and established cardiovascular disease, supported primarily by SUSTAIN‑6.[11]

• Chronic weight management/obesity

  • High‑dose subcutaneous semaglutide (2.4 mg once weekly; Wegovy) is approved in adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight‑related comorbidity, as an adjunct to reduced‑calorie diet and increased physical activity.[14][15]
  • EU and US labels broadly align in requiring chronic weight management in obesity or overweight with comorbidity.[14]

Investigational and off‑label areas

• Non‑alcoholic steatohepatitis (NASH)/MAFLD: Semaglutide is under active investigation for NASH/MAFLD, with early data suggesting histologic improvement and reductions in liver fat, but no definitively approved indication yet.[11][6]
• Obesity‑related comorbidities: Studies are exploring effects on obstructive sleep apnea, heart failure with preserved ejection fraction, and kidney disease as part of broader GLP‑1 RA research.[11][14]

Any uses outside approved indications remain investigational or off‑label and rely on limited data.

Dosing context

Doses below are descriptive of regimens used in trials and product labels and do not constitute prescribing recommendations.

• Subcutaneous semaglutide for T2D (Ozempic)

  • SUSTAIN and labeling commonly used once‑weekly doses of 0.5 mg and 1.0 mg, with initial titration from 0.25 mg once weekly to mitigate gastrointestinal adverse effects.[11]

• Oral semaglutide for T2D (Rybelsus)

  • PIONEER trials used 3 mg, 7 mg, and 14 mg once daily, often starting at 3 mg and titrating upward.[2][11] Administration requirements include fasting and intake with minimal water to maximize absorption.[2]

• Subcutaneous semaglutide for chronic weight management (Wegovy)

  • STEP trials and labeling utilize a titration to a maintenance dose of 2.4 mg once weekly, generally starting at 0.25 mg and escalating in 4‑week increments (e.g., 0.25→0.5→1.0→1.7→2.4 mg) to improve tolerability.[14][15]

• MAFLD study

  • The MAFLD/T2D cohort used 0.25 mg/week for 4 weeks, then 0.5 mg/week for 8 weeks (total 12 weeks).[6]

Dosing must be individualized under medical supervision, taking into account renal function, concomitant medications, and tolerability.

Safety profile

Common adverse effects

Across SUSTAIN, PIONEER, and STEP trials, the most frequent adverse events were gastrointestinal and dose‑dependent:[11][14][15]

• Nausea, vomiting, diarrhea, abdominal pain, and constipation.
• These typically occurred during dose escalation and often diminished over time.[11][14]

Other commonly reported effects include decreased appetite, dyspepsia, and fatigue.[14][15]

Serious and clinically significant risks

• Pancreatitis: GLP‑1 RAs, including semaglutide, have been associated with rare cases of acute pancreatitis; labeling advises discontinuation if pancreatitis is suspected.[11]
• Gallbladder disease: An increased incidence of cholelithiasis and cholecystitis has been observed, possibly related to rapid weight loss and direct effects on gallbladder motility.[11][14]
• Diabetic retinopathy complications: In SUSTAIN‑6, a higher rate of retinopathy complications was observed in semaglutide‑treated patients, particularly those with pre‑existing retinopathy and rapid improvements in glycemic control, leading to cautionary statements for patients with diabetic retinopathy.[11]
• Hypoglycemia: Semaglutide alone has a low inherent risk of hypoglycemia due to glucose‑dependent insulinotropic action; however, risk increases when combined with insulin or sulfonylureas.[11]

Contraindications and precautions

Based on GLP‑1 RA class labeling and semaglutide product information:[11][14]

• Contraindications:

  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), due to rodent C‑cell tumor findings with GLP‑1 RAs.
  • Known serious hypersensitivity to semaglutide or formulation components.

• Precautions:

  • Caution in patients with a history of pancreatitis.
  • Monitoring for gallbladder disease, especially rapid weight loss.
  • Slow titration advised to mitigate gastrointestinal intolerance.
  • Consideration of retinopathy status in patients with T2D due to possible worsening associated with rapid HbA1c reduction.[11]

Long‑term safety beyond several years remains under continued post‑marketing surveillance, although large CV outcome trials have not identified major new safety signals.[11]

Regulatory status

In the United States, semaglutide is approved by the FDA as:[2][11][14]

• Ozempic (subcutaneous): For glycemic control in adults with T2D and to reduce risk of major cardiovascular events in adults with T2D and established CVD.
• Rybelsus (oral): For glycemic control in adults with T2D.
• Wegovy (subcutaneous 2.4 mg): For chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight‑related comorbidity.

In the European Union, the European Medicines Agency (EMA) has granted analogous approvals:

• Subcutaneous semaglutide for T2D and CV risk reduction in adults with T2D and high CVD risk.
• High‑dose semaglutide for chronic weight management in adults with obesity or overweight and comorbidities.[11][14]

Semaglutide continues to be evaluated in additional indications (e.g., NASH/MAFLD and other obesity‑related conditions), but as of the latest available data, these remain investigational without formal regulatory approval.[6][11]